To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
The goal of this observational study is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:

major adverse cardiovascular events within 48 months of the trial duration
microvascular events within 48 months of the trial duration
- EligibilityCriteria: Inclusion Criteria:  Patients with type 2 diabetes diagnosed by American Diabetes Association criteria Age ≥ 19 years Non-HDL-C ≥100 mg/dL, TG ≥200, <500 mg/dL on moderate-intensity statins with cardiovascular risk factor  Exclusion Criteria:  Pregnant or breastfeeding women Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.) Patient with myopathy and rhabdomyolysis AST/ALT more than 3 ULN Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with type 2 diabetes, Dyslipidemias - SamplingMethod: Probability Sample